|
1
|
Kesic V: Management of cervical cancer.
Eur J Surg Oncol. 32:832–837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monk BJ, Tewari KS and Koh WJ:
Multimodality therapy for locally advanced cervical carcinoma:
State of the art and future directions. J Clin Oncol. 25:2952–2965.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamagami W and Aoki D: Annual report of
the committee on gynecologic oncology, the Japan society of
obstetrics and gynecology. J Obstet Gynaecol Res. 41:1861–1869.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takekuma M, Kasamatsu Y, Kado N, Kuji S,
Tanaka A, Takahashi N, Abe M and Hirashima Y: Reconsideration of
postoperative concurrent chemoradiotherapy with fluorouracil and
cisplatin for uterine cervical cancer. J Obstet Gynaecol Res.
41:1638–1643. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takeda N, Sakuragi N, Takeda M, Okamoto K,
Kuwabara M, Negishi H, Oikawa M, Yamamoto R, Yamada H and Fujimoto
S: Multivariate analysis of histopathologic prognostic factors for
invasive cervical cancer treated with radical hysterectomy and
systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol
Scand. 81:1144–1151. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh N and Arif S: Histopathologic
parameters of prognosis in cervical cancer-a review. Int J Gynecol
Cancer. 14:741–750. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasamatsu T, Onda T, Sawada M, Kato T,
Ikeda S, Sasajima Y and Tsuda H: Radical hysterectomy for FIGO
stage I–IIB adenocarcinoma of the uterine cervix. Br J Cancer.
100:1400–1405. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mabuchi Y, Yahata T, Kobayashi A, Tanizaki
Y, Shiro M, Ota N, Yagi S, Minami S and Ino K: Clinicopathologic
factors of cervical adenocarcinoma stages IB to IIB. Int J Gynecol
Cancer. 25:1677–1682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosa DD, Medeiros LR, Edelweiss MI,
Pohlmann PR and Stein AT: Adjuvant platinum-based chemotherapy for
early stage cervical cancer. Cochrane Database Syst Rev.
6:CD0053422012.PubMed/NCBI
|
|
10
|
Ryu HS, Chun M, Chang KH, Chang HJ and Lee
JP: Postoperative adjuvant concurrent chemoradiotherapy improves
survival rates for high-risk, early stage cervical cancer patients.
Gynecol Oncol. 96:490–495. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitajima K, Suzuki K, Senda M, Kita M,
Nakamoto Y, Onishi Y, Maeda T, Yoshikawa T, Ohno Y and Sugimura K:
FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med
Commun. 32:549–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanizaki Y, Kobayashi A, Shiro M, Ota N,
Takano R, Mabuchi Y, Yagi S, Minami S, Terada M and Ino K:
Diagnostic value of preoperative SUVmax on FDG-PET/CT
for the detection of ovarian cancer. Int J Gynecol Cancer.
24:454–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kitajima K, Kita M, Suzuki K, Senda M,
Nakamoto Y and Sugimura K: Prognostic significance of
SUVmax (maximum standardized uptake value) measured by
[18F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging.
39:840–845. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Antonsen SL, Loft A, Fisker R, Nielsen AL,
Andersen ES, Høgdall E, Tabor A, Jochumsen K, Fagö-Olsen CL,
Asmussen J, et al: SUVmax of 18FDG PET/CT as
a predictor of high-risk endometrial cancer patients. Gynecol
Oncol. 129:298–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura K, Hongo A, Kodama J and
Hiramatsu Y: The measurement of SUVmax of the primary
tumor is predictive of prognosis for patients with endometrial
cancer. Gynecol Oncol. 123:82–87. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gouy S, Morice P, Narducci F, Uzan C,
Gilmore J, Kolesnikov-Gauthier H, Querleu D, Haie-Meder C and
Leblanc E: Nodal-staging surgery for locally advanced cervical
cancer in the era of PET. Lancet Oncol. 13:e212–e220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kidd EA, Siegel BA, Dehdashti F, Rader JS,
Mutch DG, Powell MA and Grigsby PW: Lymph node staging by positron
emission tomography in cervical cancer: Relationship to prognosis.
J Clin Oncol. 28:2108–2113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kidd EA, Siegel BA, Dehdashti F and
Grigsby PW: The standardized uptake value for F-18
fluorodeoxyglucose is a sensitive predictive biomarker for cervical
cancer treatment response and survival. Cancer. 110:1738–1744.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ,
Lee JW, Lee JH, Bae DS and Kim BG: The prognostic significance of
the SUVmax (maximum standardized uptake value for F-18
fluorodeoxyglucose) of the cervical tumor in PET imaging for early
cervical cancer: Preliminary results. Gynecol Oncol. 115:65–68.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho SH, Lim JY, Kim SN, Hong S, Chung HW,
So Y, Kim WY and Lee SJ: The prognostic significance of
pretreatment [18F]FDG-PET/CT imaging in patients with uterine
cervical cancer: Preliminary results. Eur J Gynaecol Oncol.
36:30–35. 2015.PubMed/NCBI
|
|
21
|
Crivellaro C, Signorelli M, Guerra L, De
Ponti E, Buda A, Dolci C, Pirovano C, Todde S, Fruscio R and Messa
C: 18F-FDG PET/CT can predict nodal metastases but not
recurrence in early stage uterine cervical cancer. Gynecol Oncol.
127:131–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim BS, Kim IJ, Kim SJ, Nam HY, Pak KJ,
Kim K and Yun MS: The prognostic value of the metabolic tumor
volume in FIGO stage IA to IIB cervical cancer for tumor
recurrence: Measured by F-18 FDG PET/CT. Nucl Med Mol Imaging.
45:36–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue F, Lin LL, Dehdashti F, Miller TR,
Siegel BA and Grigsby PW: F-18 fluorodeoxyglucose uptake in primary
cervical cancer as an indicator of prognosis after radiation
therapy. Gynecol Oncol. 101:147–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun MS, Kim SJ, Pak K and Lee CH:
Additional prognostic value of SUVmax measured by F-18
FDG PET/CT over biological marker expressions in surgically
resected cervical cancer patients. Oncol Res Treat. 38:413–416.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kitajima K, Suenaga Y, Ueno Y, Maeda T,
Ebina Y, Yamada H, Okunaga T, Kubo K, Sofue K, Kanda T, et al:
Preoperative risk stratification using metabolic parameters of
(18)F-FDG PET/CT in patients with endometrial cancer. Eur J Nucl
Med Mol Imaging. 42:1268–1275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung HH, Kim JW, Han KH, Eo JS, Kang KW,
Park NH, Song YS, Chung JK and Kang SB: Prognostic value of
metabolic tumor volume measured by FDG-PET/CT in patients with
cervical cancer. Gynecol Oncol. 120:270–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoo J, Choi JY, Moon SH, Bae DS, Park SB,
Choe YS, Lee KH and Kim BT: Prognostic significance of volume-based
metabolic parameters in uterine cervical cancer determined using
18F-fluorodeoxyglucose positron emission tomography. Int
J Gynecol Cancer. 22:1226–1233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kidd EA and Grigsby PW: Intratumoral
metabolic heterogeneity of cervical cancer. Clin Cancer Res.
14:5236–5241. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tong SY, Lee JM, Ki KD, Choi YJ, Seol HJ,
Lee SK, Huh CY, Kim GY and Lim SJ: Correlation between FDG uptake
by PET/CT and the expressions of glucose transporter type 1 and
hexokinase II in cervical cancer. Int J Gynecol Cancer. 22:654–658.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park SI, Suh DS, Kim SJ, Choi KU and Yoon
MS: Correlation between biological marker expression and
F-fluorodeoxyglucose uptake in cervical cancer measured by positron
emission tomography. Onkologie. 36:169–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura K, Okumura Y, Kodama J, Hongo A,
Kanazawa S and Hiramatsu Y: The predictive value of measurement of
SUVmax and SCC-antigen in patients with pretreatment of
primary squamous cell carcinoma of cervix. Gynecol Oncol.
119:81–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan L, Cheng J, Zhou M, Yao Z and Zhang Y:
The SUVmax (maximum standardized uptake value for F-18
fluorodeoxyglucose) and serum squamous cell carcinoma antigen
(SCC-ag) function as prognostic biomarkers in patients with primary
cervical cancer. J Cancer Res Clin Oncol. 138:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miccò M, Vargas HA, Burger IA, Kollmeier
MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H and Sala E:
Combined pre-treatment MRI and 18F-FDG PET/CT parameters
as prognostic biomarkers in patients with cervical cancer. Eur J
Radiol. 83:1169–1176. 2014. View Article : Google Scholar : PubMed/NCBI
|
